vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and ENNIS, INC. (EBF). Click either name above to swap in a different company.
ENNIS, INC. is the larger business by last-quarter revenue ($100.2M vs $62.1M, roughly 1.6× Cytek Biosciences, Inc.). ENNIS, INC. runs the higher net margin — 10.8% vs -70.9%, a 81.7% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 0.4%). ENNIS, INC. produced more free cash flow last quarter ($15.7M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 1.4%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
ENNIS, INC. (ticker EBF) is a leading North American provider of printed business products and related services. Its offerings include custom business forms, pressure-sensitive labels, marketing collateral, promotional items, and branded packaging, serving clients across retail, healthcare, financial services, and small business segments.
CTKB vs EBF — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $100.2M |
| Net Profit | $-44.1M | $10.8M |
| Gross Margin | 52.9% | 31.9% |
| Operating Margin | -9.0% | 15.0% |
| Net Margin | -70.9% | 10.8% |
| Revenue YoY | 8.1% | 0.4% |
| Net Profit YoY | -557.1% | 6.1% |
| EPS (diluted) | — | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $100.2M | ||
| Q3 25 | $52.3M | $98.7M | ||
| Q2 25 | $45.6M | $97.2M | ||
| Q1 25 | $41.5M | $92.7M | ||
| Q4 24 | $57.5M | $99.8M | ||
| Q3 24 | $51.5M | $99.0M | ||
| Q2 24 | $46.6M | $103.1M | ||
| Q1 24 | $44.9M | $97.4M |
| Q4 25 | $-44.1M | $10.8M | ||
| Q3 25 | $-5.5M | $13.2M | ||
| Q2 25 | $-5.6M | $9.8M | ||
| Q1 25 | $-11.4M | $9.0M | ||
| Q4 24 | $9.6M | $10.2M | ||
| Q3 24 | $941.0K | $10.3M | ||
| Q2 24 | $-10.4M | $10.7M | ||
| Q1 24 | $-6.2M | $10.1M |
| Q4 25 | 52.9% | 31.9% | ||
| Q3 25 | 52.7% | 30.5% | ||
| Q2 25 | 52.3% | 31.1% | ||
| Q1 25 | 48.6% | 29.5% | ||
| Q4 24 | 58.5% | 29.3% | ||
| Q3 24 | 56.3% | 30.1% | ||
| Q2 24 | 54.6% | 30.0% | ||
| Q1 24 | 51.3% | 28.4% |
| Q4 25 | -9.0% | 15.0% | ||
| Q3 25 | -17.6% | 12.5% | ||
| Q2 25 | -23.3% | 13.7% | ||
| Q1 25 | -36.1% | 13.0% | ||
| Q4 24 | 5.2% | 13.1% | ||
| Q3 24 | -8.2% | 13.3% | ||
| Q2 24 | -18.3% | 13.3% | ||
| Q1 24 | -23.9% | 13.3% |
| Q4 25 | -70.9% | 10.8% | ||
| Q3 25 | -10.5% | 13.3% | ||
| Q2 25 | -12.2% | 10.1% | ||
| Q1 25 | -27.5% | 9.7% | ||
| Q4 24 | 16.8% | 10.2% | ||
| Q3 24 | 1.8% | 10.4% | ||
| Q2 24 | -22.4% | 10.4% | ||
| Q1 24 | -13.8% | 10.4% |
| Q4 25 | — | $0.42 | ||
| Q3 25 | — | $0.51 | ||
| Q2 25 | — | $0.38 | ||
| Q1 25 | — | $0.34 | ||
| Q4 24 | — | $0.39 | ||
| Q3 24 | — | $0.40 | ||
| Q2 24 | — | $0.41 | ||
| Q1 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $31.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $304.8M |
| Total Assets | $461.5M | $354.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $31.3M | ||
| Q3 25 | $93.3M | $31.9M | ||
| Q2 25 | $75.5M | $32.6M | ||
| Q1 25 | $95.3M | $72.5M | ||
| Q4 24 | $98.7M | $68.6M | ||
| Q3 24 | $162.3M | $122.6M | ||
| Q2 24 | $177.9M | $123.7M | ||
| Q1 24 | $168.8M | $110.9M |
| Q4 25 | $341.7M | $304.8M | ||
| Q3 25 | $378.6M | $305.4M | ||
| Q2 25 | $377.6M | $301.2M | ||
| Q1 25 | $379.6M | $302.0M | ||
| Q4 24 | $395.7M | $297.7M | ||
| Q3 24 | $385.5M | $358.4M | ||
| Q2 24 | $389.1M | $354.4M | ||
| Q1 24 | $392.6M | $349.8M |
| Q4 25 | $461.5M | $354.3M | ||
| Q3 25 | $494.9M | $361.8M | ||
| Q2 25 | $493.3M | $361.7M | ||
| Q1 25 | $482.6M | $348.9M | ||
| Q4 24 | $499.5M | $346.1M | ||
| Q3 24 | $491.2M | $406.8M | ||
| Q2 24 | $483.7M | $406.2M | ||
| Q1 24 | $492.1M | $399.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $16.4M |
| Free Cash FlowOCF − Capex | $-1.8M | $15.7M |
| FCF MarginFCF / Revenue | -2.9% | 15.7% |
| Capex IntensityCapex / Revenue | 1.6% | 0.7% |
| Cash ConversionOCF / Net Profit | — | 1.52× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $42.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $16.4M | ||
| Q3 25 | $-3.9M | $10.5M | ||
| Q2 25 | $108.0K | $8.0M | ||
| Q1 25 | $-125.0K | $12.8M | ||
| Q4 24 | $2.0M | $18.2M | ||
| Q3 24 | $13.2M | $11.8M | ||
| Q2 24 | $6.2M | $23.1M | ||
| Q1 24 | $4.0M | $16.6M |
| Q4 25 | $-1.8M | $15.7M | ||
| Q3 25 | $-4.6M | $9.0M | ||
| Q2 25 | $-1.5M | $6.6M | ||
| Q1 25 | $-974.0K | $11.1M | ||
| Q4 24 | $1.1M | $17.5M | ||
| Q3 24 | $12.2M | $10.7M | ||
| Q2 24 | $5.2M | $20.6M | ||
| Q1 24 | $3.4M | $15.0M |
| Q4 25 | -2.9% | 15.7% | ||
| Q3 25 | -8.7% | 9.2% | ||
| Q2 25 | -3.2% | 6.8% | ||
| Q1 25 | -2.3% | 12.0% | ||
| Q4 24 | 1.9% | 17.6% | ||
| Q3 24 | 23.7% | 10.8% | ||
| Q2 24 | 11.0% | 20.0% | ||
| Q1 24 | 7.6% | 15.3% |
| Q4 25 | 1.6% | 0.7% | ||
| Q3 25 | 1.3% | 1.4% | ||
| Q2 25 | 3.5% | 1.4% | ||
| Q1 25 | 2.0% | 1.8% | ||
| Q4 24 | 1.6% | 0.6% | ||
| Q3 24 | 2.0% | 1.1% | ||
| Q2 24 | 2.3% | 2.4% | ||
| Q1 24 | 1.3% | 1.7% |
| Q4 25 | — | 1.52× | ||
| Q3 25 | — | 0.80× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | 0.21× | 1.78× | ||
| Q3 24 | 14.05× | 1.15× | ||
| Q2 24 | — | 2.16× | ||
| Q1 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
EBF
Segment breakdown not available.
